23,095 research outputs found
Ustekinumab for the treatment of psoriatic arthritis: an update.
Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis
Psoriatic Arthritis and Diabetes: A Population-Based Cross-Sectional Study
Background. Diabetes has been associated with psoriasis, but little is known about the association between psoriatic arthritis and diabetes. Methods. Patients diagnosed with psoriatic arthritis by a rheumatologist were compared to age- and sex-matched patients without psoriatic arthritis regarding the prevalence of diabetes in a population-based cross-sectional study using logistic multivariate models. The study was performed utilizing the medical database of Clalit, the largest healthcare provider organization in Israel. Results. The study included 549 patients with psoriatic arthritis ≥21 years and 1,098 patients without psoriatic arthritis. The prevalence of diabetes in patients with psoriatic arthritis was increased as compared to the prevalence in patients without psoriatic arthritis (15.3% versus 10.7%, value = 0.008). The difference was prominent among females (18.7% versus 10.3%, ) but not among males (11.2% in patients with and without psoriatic arthritis, ). In a multivariate analysis, psoriatic arthritis was associated with diabetes among females (OR = 1.60, 95% CI: 1.02–2.52, ) but not among males (OR = 0.71, 95% CI: 0.42–1.22, ). Conclusion. Our study suggests a possible association between psoriatic arthritis and diabetes in women. Women with psoriatic arthritis might be candidates for diabetes screening
Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis.
ImportanceWhile "omics" studies have advanced our understanding of inflammatory skin diseases, metabolomics is mostly an unexplored field in dermatology.ObjectiveWe sought to elucidate the pathogenesis of psoriatic diseases by determining the differences in metabolomic profiles among psoriasis patients with or without psoriatic arthritis and healthy controls.DesignWe employed a global metabolomics approach to compare circulating metabolites from patients with psoriasis, psoriasis and psoriatic arthritis, and healthy controls.SettingStudy participants were recruited from the general community and from the Psoriasis Clinic at the University of California Davis in United States.ParticipantsWe examined metabolomic profiles using blood serum samples from 30 patients age and gender matched into three groups: 10 patients with psoriasis, 10 patients with psoriasis and psoriatic arthritis and 10 control participants. Main outcome(s) and measures(s): Metabolite levels were measured calculating the mean peak intensities from gas chromatography time-of-flight mass spectrometry.ResultsMultivariate analyses of metabolomics profiles revealed altered serum metabolites among the study population. Compared to control patients, psoriasis patients had a higher level of alpha ketoglutaric acid (Pso: 288 ± 88;Control209 ± 69; p=0.03), a lower level of asparagine (Pso: 5460 ± 980;Control7260 ± 2100; p=0.02), and a lower level of glutamine (Pso: 86000 ± 20000;Control111000 ± 27000; p=0.02). Compared to control patients, patients with psoriasis and psoriatic arthritis had increased levels of glucuronic acid (Pso + PsA: 638 ± 250;Control347 ± 61; p=0.001). Compared to patients with psoriasis alone, patients with both psoriasis and psoriatic arthritis had a decreased level of alpha ketoglutaric acid (Pso + PsA: 186 ± 80; Pso: 288 ± 88; p=0.02) and an increased level of lignoceric acid (Pso + PsA: 442 ± 280; Pso: 214 ± 64; p=0.02).Conclusions and relevanceThe metabolite differences help elucidate the pathogenesis of psoriasis and psoriatic arthritis and they may provide insights for therapeutic development
Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis
Objective: To calculate the persistence, over a period of eight years, the
retention rate of first and second-line of treatment with biological agents
in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis
and to compare retention rates of the various drugs for each pathology.
Method: Retrospective observational study that included patients affected
by rheumatoid arthritis, spondyloarthritis and psoriatic arthritis, who
started treatment with biological agents between January 2009 and December
2012 and followed until December 2016.
Results: 132, 87 and 33 patients were included in rheumatoid arthritis,
spondyloarthritis and psoriatic arthritis, respectively. The median retention
duration of all biological agents for the first and second-line, was 30.9
months and 14.0 months, respectively for rheumatoid arthritis; 63.06 months
and 25.6 months, respectively in spondyloarthritis. Psoriatic arthritis did not
reach the median (> 70 months in first-line) (first line p = 0.002). Individual
drug survival in first line: the median retention duration of tocilizumab was
58.3 months, followed by etanercept (p = 0.79) in rheumatoid arthritis. For
spondyloarthritis, golimumab and etanercept had greater retention than the
other drugs (they did not reach the median): adalimumab was 63.0 months
and for infliximab was 50.1 months. In psoriatic arthritis, golimumab, infliximab
and etanercept not reach the median and they had greater retention
arthritis, and golimumab for spondyloarthritis and psoriatic arthritis.
Conclusions: Tocilizumab and etanercept in rheumatoid arthritis, and
golimumab in spondyloarthritis and psoriatic arthritis also, were the most
persistent drugs in first-line and second-line treatmentObjetivo: Calcular y analizar la persistencia global y por medicamento,
en primera y segunda lĂnea de tratamiento, en pacientes con artritis reumatoide,
espondiloartritis axial radiográfica y no radiográfica y artritis psoriásica
durante un periodo de ocho años.
MĂ©todo: Estudio retrospectivo observacional de persistencia en pacientes
que iniciaron su terapia con medicamentos biolĂłgicos entre enero de
2009 y diciembre de 2012 en seguimiento hasta diciembre de 2016.
Resultados: Se analizaron 132, 87 y 33 pacientes con artritis reumatoide,
espondiloartritis y artritis psoriásica, respectivamente. La persistencia
mediana global para los biolĂłgicos en primera y segunda lĂnea fueron:
30,9 meses y 14 meses, respectivamente, en artritis reumatoide; 63,06
meses y 25,6 meses en espondiloartritis. No se alcanzĂł la persistencia
mediana en los ocho años de seguimiento en artritis psoriásica (> 70
meses) (p = 0,002 para la funciĂłn de supervivencia entre patologĂas en
primera lĂnea). Persistencia mediana alcanzada en primera lĂnea por medicamento:
tocilizumab (58,3 meses), seguido de etanercept (44 meses)
en artritis reumatoide (p = 0,79); en espondiloartritis golimumab y etanercept
fueron los más persistentes (no alcanzaron la mediana), seguidos de
adalimumab (44 meses) e infliximab (50,1 meses). En artritis psoriásica,
golimumab seguido de infliximab y etanercept fueron los más persistentes
(no alcanzaron la mediana), y adalimumab (59,4 meses). Persistencia
mediana alcanzada en segunda lĂnea por medicamento: tocilizumab
(22,1 meses) en artritis reumatoide. Golimumab fue el más persistente en
espondiloartritis y artritis psoriásica (sin alcanzar la mediana).
Conclusiones: Tocilizumab y etanercept fueron los medicamentos más
persistentes en artritis reumatoide, y golimumab en espondiloartritis y artritis
psoriásica en primera y segunda lĂnea de tratamient
Tumor necrosis factor inhibitors in psoriatic arthritis.
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially. The clinical efficacy and the inhibition of radiographic progression demonstrated by TNFi have transformed the management of PsA. However, there is still an unmet need for a subset of patients who do not respond adequately to TNFi. Areas covered: This review provides an overview of the pharmacokinetics of TNFi, the efficacy of TNFi in PsA, and the role of immunogenicity of TNFi in the treatment of PsA. In addition, we address the use of TNFi in the setting of other medications utilized in the treatment of PsA and the potential future role of biosimilars. Expert commentary: Monoclonal antibodies exhibit complex and widely variable pharmacokinetics. The study of factors that can affect the pharmacokinetics, such as immunogenicity, is valuable to further define and understand the use of TNFi in PsA, especially in the subset of patients who do not respond adequately to these agents or lose effectiveness over time
Recommended from our members
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives.
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to biologics, is effective in the management of treatment resistant disease, and is reported to improve enthesitis, dactylitis, and radiographic progression. Tofacitinib is also associated with an increased risk of serious infections, malignancy, and laboratory abnormalities. There is currently a large armamentarium of therapies for psoriatic arthritis, and choosing among treatments can be challenging. Due to this wide selection, a thorough assessment of psoriatic disease phenotype, patient preference, disease presentation, and comorbidities is critical. This review addresses key considerations in patient selection for the treatment of PsA with tofacitinib
Recommended from our members
Clinical and Genetic Risk Factors Associated with Psoriatic Arthritis among Patients with Psoriasis.
IntroductionPsoriatic arthritis (PsA) is a chronic, inflammatory arthritis that affects an estimated 30% of patients with psoriasis. PsA is underdiagnosed in primary care and dermatology clinics due to a variety of reasons, including failure of healthcare providers to ask about symptoms, overlap of symptoms and signs with other rheumatologic conditions, and lack of a specific diagnostic test. A delay in PsA diagnosis and treatment, even as short as 6Â months, can lead to decreased quality of life, increased joint damage, and worse long-term physical function. In this study, we sought to identify the clinical and genetic factors that help discriminate patients with PsA from those with cutaneous psoriasis only.MethodsWe analyzed a cohort of 974 psoriasis patients at an academic medical center, of whom 175 had confirmed PsA, and performed univariate, multivariate, and predictive modeling to determine factors associated with PsA.ResultsThe univariate analysis revealed significant positive associations of PsA with age, nail involvement, scalp involvement, skin fold involvement, elbow/knee involvement, psoriasis severity, plaque subtype, erythrodermic subtype, hypertension, type 2 diabetes, and coronary artery disease, and a significant negative association of PsA with the human leukocyte antigen (HLA)-C*06:02 allele. In the multivariate analysis, nail involvement, type 2 diabetes, and pustular psoriasis remained significantly associated with PsA, while HLA-C*06:02 positivity remained protective. There was a trend towards an association of PsA with older age, younger age of psoriasis onset, and skin fold involvement, while there was protective trend for smoking. A predictive model including both clinical and genetic factors showed reasonable discriminative ability between psoriasis and PsA, with an area under the curve of 0.87 for a receiver operating characteristic curve.ConclusionThis study identified a number of clinical and genetic features that could help stratify patients who are at higher risk for having PsA and for whom rheumatology referral may be beneficial
Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
Objectives: To determine the proportion of patients with psoriatic arthritis in the Adalimumab Effectiveness in Psoriatic Arthritis trial achieving minimal disease activity (MDA) and its individual components at 1 or more visits over 144 weeks, identify baseline predictors of MDA achievement, and evaluate the association of MDA status with independent quality of life (QoL)-related patient-reported outcomes (PROs).
Methods: Univariate and multivariate analyses were used to identify the baseline characteristics that predicted achievement of MDA at individual time points (weeks 12 through 144) or sustained MDA (achievement of MDA at 2 consecutive time points 12 weeks apart). The association of independent QoL-related PROs with MDA achievement was evaluated at weeks 24 and 144.
Results: In univariate analyses, higher baseline patient assessment of pain, tender joint count (TJC), enthesitis and Health Assessment Questionnaire-Disability Index (HAQ-DI) score were significantly associated with lower likelihood of achieving MDA at later time points. Multivariate analyses confirmed higher baseline HAQ-DI as a significant predictor for failure to achieve MDA at later time points. Achievement of sustained MDA was associated with lower baseline TJC and HAQ-DI score. Achievement of different MDA components appeared to be treatment dependent. MDA achievers had significantly better QoL-related PROs and greater improvements in PROs from baseline to week 24 compared with non-achievers.
Conclusions: Higher HAQ-DI score was the most consistent baseline factor that decreased the likelihood of achieving MDA and sustained MDA at later time points. Achieving MDA was associated with better independent QoL-related PROs
Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison
Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor necrosis factor (TNF)-naïve populations. Individual patient data from the FUTURE 2 RCT (secukinumab vs. placebo; N = 299) were adjusted to match baseline characteristics of the ADEPT RCT (adalimumab vs. placebo; N = 313). Logistic regression determined adjustment weights for age, body weight, sex, race, methotrexate use, psoriasis affecting ≥ 3% of body surface area, Psoriasis Area and Severity Index score, Health Assessment Questionnaire Disability Index score, presence of dactylitis and enthesitis, and previous anti-TNF therapy. Recalculated secukinumab outcomes were compared with adalimumab outcomes at weeks 12 (placebo-adjusted), 16, 24, and 48 (nonplacebo-adjusted). After matching, the effective sample size for FUTURE 2 was 101. Week 12 American College of Rheumatology (ACR) response rates were not significantly different between secukinumab and adalimumab. Week 16 ACR 20 and 50 response rates were higher for secukinumab 150 mg than for adalimumab (P = 0.017, P = 0.033), as was ACR 50 for secukinumab 300 mg (P = 0.030). Week 24 ACR 20 and 50 were higher for secukinumab 150 mg than for adalimumab (P = 0.001, P = 0.019), as was ACR 20 for secukinumab 300 mg (P = 0.048). Week 48 ACR 20 was higher for secukinumab 150 and 300 mg than for adalimumab (P = 0.002, P = 0.027), as was ACR 50 for secukinumab 300 mg (P = 0.032). In our analysis, patients with PsA receiving secukinumab were more likely to achieve higher ACR responses through 1 year (weeks 16-48) than those treated with adalimumab. Although informative, these observations rely on a subgroup of patients from FUTURE 2 and thus should be considered interim until the ongoing head-to-head RCT EXCEED can validate these findings. Novartis Pharma AG
Recommended from our members
Secukinumab in the treatment of psoriasis: patient selection and perspectives.
Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab has proven to be both highly efficacious and well-tolerated. However, several biologic medications are currently approved for the treatment of moderate-to-severe plaque psoriasis, and many demonstrate excellent efficacy and safety. Due to this wide selection, it is often unclear how to choose biologics for specific patients. Important considerations in biologic selection include clinical efficacy, safety, cost, convenience, onset of action, and management of comorbid disease. This article aims to outline the key considerations in patient selection for the treatment of plaque psoriasis with secukinumab
- …